Jennifer Chain | CSM Industry Advocate
The Leukopak Lady | United States
Jennifer Chain, PhD, CABP, is a scientist with more than 27 years of experience spanning T cell research, product development, blood banking, and cell therapy. She is a thought leader in the field of cellular starting materials, focusing on leukopak collection, donor stewardship, and donor screening strategies. Previously, Dr. Chain led a program to collect leukopaks and bone marrow from healthy donors to support allogeneic cell therapy development and manufacturing. She oversaw over 1000 collections from donor recruitment through product shipping and led several collection-focused clinical trials. Her expertise extends across the cell and gene therapy field, including educational program development, strategic planning, project management, business development, marketing, and advocacy. She has adopted the persona “The Leukopak Lady” for her short videos demystifying cellular starting materials.
Appearances:
Festival of Biologics Day 1 @ 15:30
Why Qualifying Donors Early is Essential to the Success of Your Allogeneic Cell Therapy
· Donor qualification is a critical upstream element of allogeneic cell therapy manufacturing, and early donor decisions influence product consistency, scalability, and overall program success.
· Regulatory expectations for donor qualification support GMP manufacturing, with regulators increasingly focused on control and characterization of donor attributes and donor cell function.
· The downstream consequences of inadequate donor qualification can be significant, including increased clinical variability, manufacturing risk, regulatory delays, and threats to product approval.
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events